Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

103
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
103
Complement System01:27

Complement System

2.5K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.5K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

756
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
756
Positive Symptoms Schizophrenia: Hallucinations and Delusions01:26

Positive Symptoms Schizophrenia: Hallucinations and Delusions

107
Schizophrenia is a complex psychiatric disorder characterized by a range of symptoms that significantly impact cognition, behavior, and emotional regulation. Among these, the positive symptoms stand out as they involve the addition or exaggeration of normal mental functions, deviating markedly from typical behavior and perception. Hallucinations and delusions are prominent positive symptoms, each profoundly affecting the individual's experience of reality.
Hallucinations
Hallucinations in...
107
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

145
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
145
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

96
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
96

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Association between changes in sleep quality and serum pro-inflammatory cytokine levels in patients with major depressive disorder following duloxetine treatment.

Annals of general psychiatry·2026
Same author

Effect of age, sex, and BMI on serum olanzapine levels and their correlation with metabolic parameters and serum pro-inflammatory cytokine levels in schizophrenia patients.

BMC psychiatry·2026
Same author

Alterations in serum melatonin, IL-6 and BDNF levels and their clinical correlations in first-episode major depressive disorder.

Annals of general psychiatry·2026
Same author

Prefrontal cortex-extracellular vesicle RNAs coupling in alcohol use disorder: towards non-invasive biomarkers and targeted therapeutics.

Artificial cells, nanomedicine, and biotechnology·2026
Same author

Bone marrow mesenchymal stem cell exosome-derived miR-223 regulated cellular pyroptosis of macrophage in osteomyelitis through regulating LACC1.

Scientific reports·2025
Same author

Associations of ANKK1 (rs1800497) polymorphism with glucose and lipid metabolism in patients with schizophrenia treated with olanzapine: a retrospective study.

Annals of general psychiatry·2025

相关实验视频

Updated: Jul 25, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K

基于外周补充因子的生物标志物,用于第一发精神分裂症患者.

Yin Cao1,2,3,4, Yayun Xu5,6,7, Qingrong Xia1,2,3,4

  • 1Affiliated Psychological Hospital of Anhui Medical University, Hefei, People's Republic of China.

Neuropsychiatric disease and treatment
|June 29, 2023
PubMed
概括

血清补充因子C1,C2,C3,C4和CH50显示出潜力作为诊断精神分裂症 (SCZ) 的生物标志物. 在SCZ患者中升高的水平表明它们在早期检测和了解疾病中的有用性.

关键词:
生物标志物生物标志物补充因素是补充因素.诊断 诊断 诊断 诊断 诊断 诊断精神分裂症是一种精神分裂症.血液中的血清是血清.

更多相关视频

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.3K

相关实验视频

Last Updated: Jul 25, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.3K

科学领域:

  • 神经科学是一个神经科学.
  • 免疫学 免疫学 免疫学
  • 生物标志物发现发现

背景情况:

  • 精神分裂症 (SCZ) 是一种严重的神经疾病,影响全球数百万人.
  • 识别可靠的生物标志物对于早期诊断,了解病原和预后至关重要.
  • 补体系统是免疫系统的关键组成部分,因其在神经系统疾病中的作用而越来越多地被探索.

研究的目的:

  • 研究血清补充因子作为首发精神分裂症 (SCZ) 的潜在诊断生物标志物.
  • 用补充因子水平将SCZ患者与健康对照区分开来.
  • 探索补充因子度与SCZ症状严重程度之间的相关性.

主要方法:

  • 这项研究包括89名第一期SCZ患者和89名健康对照.
  • 使用ELISA测量了五种补充因子 (C1,C2,C3,C4,CH50) 的血清水平.
  • 接收器操作特征 (ROC) 曲线分析评估了诊断价值;皮尔森的相关性检查了与症状尺度 (BPRS,SANS,SAPS) 的关系.

主要成果:

  • 与对照组相比,SCZ患者观察到C1,C2,C3,C4和CH50的血清水平显著增加.
  • 这些补充因子的组合小组在歧视性SCZ患者中实现了0.857的AUC.
  • 血清中C2,C3和CH50的水平与SANS,SAPS和BPRS分别的得分呈正相关.

结论:

  • 循环补充因子 (C1,C2,C3,C4,CH50) 显示为第一个情节精神分裂症的诊断生物标志物.
  • 这些发现支持补充系统在SCZ病理生理学中的作用.
  • 进一步的研究可以为临床诊断工具验证这些因素.